Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
Gutner CA, van der Valk M, Portilla J, Jeanmaire E, Belkhir L, Lutz T, DeMoor R, Trehan R, Scherzer J, Pascual-Bernáldez M, Ait-Khaled M, Hernandez B, de Ruiter A, Anand SB, Low EL, Hadi M, Barnes N, Sevdalis N, Mohammed P, Czarnogorski M. Gutner CA, et al. Among authors: portilla j. J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241269837. doi: 10.1177/23259582241269837. J Int Assoc Provid AIDS Care. 2024. PMID: 39221544 Free PMC article.
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
Scholten S, Cahn P, Portilla J, Bisshop F, Hodder S, Ruane P, Kaplan R, Wynne BR, Man CY, Grove R, Wang R, Jones B, Ait-Khaled M, Kisare M, Okoli C. Scholten S, et al. Among authors: portilla j. Open Forum Infect Dis. 2024 Jul 1;11(7):ofae365. doi: 10.1093/ofid/ofae365. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39015350 Free PMC article. Clinical Trial.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group. Molina JM, et al. J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10. J Antimicrob Chemother. 2009. PMID: 19515730 Clinical Trial.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group. Molina JM, et al. Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25. Lancet HIV. 2018. PMID: 29592840 Clinical Trial.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team. Orrell C, et al. Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Lancet HIV. 2017. PMID: 28729158 Clinical Trial.
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS Cohort. Berenguer J, et al. Among authors: portilla j. J Infect Dis. 2024 Aug 16;230(2):421-425. doi: 10.1093/infdis/jiae168. J Infect Dis. 2024. PMID: 38557859
The future of antiretroviral therapy: challenges and needs.
Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F; HIV 2020 Project. Moreno S, et al. J Antimicrob Chemother. 2010 May;65(5):827-35. doi: 10.1093/jac/dkq061. Epub 2010 Mar 12. J Antimicrob Chemother. 2010. PMID: 20228080 Review.
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Pérez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Mariño A, Crespo M, Hernández-Quero J, Iribarren JA, Gutiérrez F, Terrón A, Esteban H, Pérez-Molina JA; GESIDA 7011 Study Group members. Pérez-Valero I, et al. J Antimicrob Chemother. 2018 Sep 1;73(9):2444-2451. doi: 10.1093/jac/dky212. J Antimicrob Chemother. 2018. PMID: 29897573 Free article. Clinical Trial.
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group. Raffi F, et al. Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8. Lancet. 2013. PMID: 23306000 Clinical Trial.
348 results